Novo Nordisk's Wegovy 7.2 mg Single-Dose Pen Recommended for EU Approval
Event summary
- CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen for obesity treatment.
- STEP UP trial shows 20.7% mean weight loss with Wegovy® 7.2 mg, and 31.2% of patients achieving ≥25% weight loss.
- Novo Nordisk expects to launch Wegovy® 7.2 mg in the EU in Q3 2026.
- Wegovy® 7.2 mg is already approved in the US and UK under the brand name Wegovy® HD.
The big picture
Novo Nordisk's CHMP recommendation for Wegovy® 7.2 mg in a single-dose pen solidifies its leadership in the obesity treatment market. The approval comes as demand for effective weight management solutions continues to rise, driven by increasing global obesity rates. The strategic shift to a single-dose pen format enhances convenience, potentially boosting adoption and market penetration. The company's ability to maintain its competitive edge will depend on execution and regulatory agility.
What we're watching
- Market Expansion
- The pace at which Novo Nordisk can scale Wegovy® 7.2 mg in the EU following Q3 2026 launch.
- Competitive Dynamics
- How Eli Lilly and other competitors respond to Novo Nordisk's strengthened obesity treatment portfolio.
- Regulatory Execution
- Whether the EMA's approval process will face any delays or additional scrutiny.
Related topics